Relay Therapeutics gains capital via licensing, reduces costs, and advances its promising PI3K-alpha inhibitor. See why RLAY ...

Itovebi targets PI3K-alpha protein, inhibiting cancer cell growth and potentially killing cancer cells. The triplet regimen demonstrated a significant overall survival benefit, a first for PI3K ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...